Open Access Open Access  Accesso riservato Abbonamento o quota di accesso

Valutazione dei rischi connessi all’utilizzo di prodotti farmaceutici e parafarmaceutici contenenti piante medicinali

Cristiano Colalto

DOI: https://doi.org/10.7175/pmeal.v6i1.299

Abstract

[Evaluation of risks related to the use of pharmaceutical and parapharmaceutical herbal products]

The increasing interest in natural and complementary products for the treatment of many different diseases leads to important concern about their safety. Phytotherapy and dietary supplementation with herbal products can be useful in clinical practice, but health care professionals should carefully consider a comprehensive clinical risk assessment. Recognition of adverse events related to the use of medicinal herbs should involve a complete analysis of their main characteristics, together with the assessment of patients’ clinical conditions, concomitant drug intake and history of use. This process is important, not only because it may prevent adverse events, but also to improve pharmacovigilance reports.

Parole chiave

Phytotherapy; Herbal medicines; Pharmacovigilance; Clinical risk assessment

Testo completo

HTML PDF

Riferimenti bibliografici

  • De Smet PAGM. Clinical risk management of herb-drug interactions. Br J Pharmacol 2006; 63: 258-67
  • U.S. Department of Health and Human Services, Office of Inspector General. Adverse event reporting for dietary supplements: an inadequate safety valve 2001 [cited 1 Feb 2012]. Disponibile su: http://oig.hhs.gov/oei/reports/oei-01-00-00180.pdf
  • Barnes J, Mills SY, Abbot NC, et al. Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face- to-face interviews with 515 users of herbal remedies. Br J Clin Pharmacol 1998; 45: 496-500
  • Cuzzolin L, Zaffani S, Benoni G. Safety implications regarding use of phytomedicines. Eur J Clin Pharmacol 2006; 62: 37-42
  • Fugh-Berman A, Ernst E. Herb-drug interactions: a review and assessment of report reliability. Br J Clin Pharmacol 2001; 51: 587-95
  • Chen ST, Dou J, Temple R, et al. New therapies from old medicines. Nat Biotechnol 2008; 26: 1077-83
  • Directive 2004/24/EC of the European Parliament and of the Council of 31 March 2004. Official Journal of the European Union. Disponibile su: http://ec.europa.eu/health/files/eudralex/vol-1/dir_2004_24/dir_2004_24_en.pdf [ultimo accesso: gennaio 2012]
  • European Medicines Agency. Community herbal monographs. Disponibile su: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000212.jsp&mid=WC0b01ac058003380a [ultimo accesso: gennaio 2012]
  • Ministero della Salute. Alimenti particolari, integratori e novel food. Autorizzazione alla produzione. Disponibile su: http://www.salute.gov.it/alimentiParticolariIntegratori/paginaInternaMenuAlimentiParticolariIntegratori.jsp?id=1272&menu=strumentieservizi [ultimo accesso: gennaio 2012]
  • Schilter B, Andersson C, Anton R, et al. Guidance for the safety assessment of botanicals and botanical preparations for use in food and food supplements. Food Chem Toxicol 2003; 41: 1625-49
  • Ruparel P, Lockwood B. The quality of commercially available herbal products. Nat Prod Commun 2011; 6: 733-44
  • De Smet PAGM. Herbal remedies. N Engl J Med 2002; 347: 2046-56
  • Gilroy CM, Steiner JF, Byers T, et al. Echinacea and truth in labeling. Arch Intern Med 2003; 163: 699-704
  • Medicines and Healthcare products Regulatory Agency. Important Safety Information: Acute poisoning from Coleus forskohlii containing products. Disponibile su: http://www.mhra.gov.uk/home/groups/es-herbal/documents/websiteresources/con009288.pdf [ultimo accesso: gennaio 2012]
  • Giancotti V. Sviluppo di metodiche HPLC-MS per la determinazione di principi attivi in prodotti di origine vegetale (tesi di laurea). Università di Torino: anno accademico 2004-2005. Disponibile su: http://aperto.unito.it/bitstream/2318/81/1/tesi_laurea_fulltext.pdf [ultimo accesso: gennaio 2012]
  • Gloro R, Hourmand-Ollivier I, Mosquet B, et al. Fulminant hepatitis during self-medication with hydroalcoholic extract of green tea. Eur J Gastroenterol Hepatol 2005; 17: 1135-7
  • Mazzanti G, Menniti-Ippolito F, Moro PA, et al. Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol 2009; 65: 331-41
  • Capasso F, D’Argenio G. L’abuso dei lassativi. Milano: Springer, 2007
  • Kasper S, Gastpar M, Möller HJ, et al. Better tolerability of St. John’s wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression. Int Clin Psychopharmacol 2010; 25: 204-13
  • Mai I, Bauer S, Perloff ES, et al. Hyperforin content determines the magnitude of the St John’s wort-cyclosporine drug interaction. Clin Pharmacol Ther 2004; 76: 330-40
  • Zhang ZJ, Tan QR, Tong Y, et al. An epidemiological study of concomitant use of Chinese medicine and antipsychotics in schizophrenic patients: implication for herb-drug interaction. PLoS One 2011; 6: e17239
  • May FE, Stewart RB, Cluff LE. Drug interactions and multiple drug administration. Clin Pharmacol Ther 1977; 22(3): 322-8
  • Onder G, Pedone C, Landi F, et al. Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). J Am Geriatr Soc 2002; 50: 1962-8
  • Safran DG, Neuman P, Schoen C, et al. Prescription drug coverage and seniors: findings from a 2003 national survey. Health Aff (Millwood) 2005; Suppl Web Exclusives: W5-152-W5-166
  • Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002; 287: 337-44
  • Williams ME, Pulliam CC, Hunter R, et al. The short-term effect of interdisciplinary medication review on function and cost in ambulatory elderly people. J Am Geriatr Soc 2004; 52: 93-8
  • Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-5
  • Yin OQP, Tomlinson B, Waye MMY, et al. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004; 14: 841-50
  • Schwarz UI, Hanso H, Oertel R, et al. Induction of intestinal P-glycoprotein by St John’s wort reduces the oral biovailability of talinolol. Clin Pharmacol Ther 2007; 81: 669-78
  • Rousseaux CG, Schachter H. Regulatory issues concerning the safety, efficacy and quality of herbal remedies. Birth Defects Res B Dev Reprod Toxicol 2003; 68: 505-10
  • Marsh J, Hager C, Havey T, et al. Use of Alternative Medicines by Patients with OA that Adversely Interact with Commonly Prescribed Medications. Clin Orthop Relat Res 2009; 467: 2705-22
  • Glisson JK, Walker LA. How physicians should evaluate dietary supplements. Am J Med 2010; 123: 577-82

Statistiche

Abstract: 695 visualizzazioni
HTML: 941 visualizzazioni
PDF: 2 visualizzazioni

Refback

  • Non ci sono refbacks, per ora.


Copyright (c) 2012

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.